MaxCyte, Inc. $MXCT Shares Bought by Mirabella Financial Services LLP

Mirabella Financial Services LLP grew its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 24.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,200,000 shares of the company’s stock after purchasing an additional 1,600,000 shares during the quarter. MaxCyte comprises approximately 1.1% of Mirabella Financial Services LLP’s portfolio, making the stock its 16th largest holding. Mirabella Financial Services LLP owned approximately 7.69% of MaxCyte worth $12,956,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Epacria Capital Partners LLC increased its holdings in shares of MaxCyte by 178.2% in the second quarter. Epacria Capital Partners LLC now owns 62,133 shares of the company’s stock valued at $135,000 after purchasing an additional 39,796 shares during the last quarter. AXA S.A. lifted its position in MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after buying an additional 1,215,481 shares in the last quarter. UBS Group AG boosted its stake in MaxCyte by 186.3% during the third quarter. UBS Group AG now owns 474,487 shares of the company’s stock worth $750,000 after buying an additional 308,769 shares during the last quarter. Lazard Asset Management LLC boosted its stake in MaxCyte by 94.2% during the second quarter. Lazard Asset Management LLC now owns 284,498 shares of the company’s stock worth $620,000 after buying an additional 137,983 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in MaxCyte by 122.8% in the 3rd quarter. XTX Topco Ltd now owns 389,071 shares of the company’s stock valued at $615,000 after buying an additional 214,405 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MXCT has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Sunday. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.00.

MaxCyte Stock Performance

MXCT opened at $0.73 on Thursday. MaxCyte, Inc. has a one year low of $0.64 and a one year high of $3.30. The stock has a market capitalization of $77.98 million, a PE ratio of -1.66 and a beta of 1.22. The business’s 50 day moving average price is $0.93 and its 200 day moving average price is $1.34.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.